Skip to search formSkip to main contentSkip to account menu

Cisplatin

Known as: Cisplatina, Cysplatyna, Cis-platinum II Diamine Dichloride 
An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged… 
National Institutes of Health

Related topics

Related topics

49 relations

Broader (1)

Antineoplastic Agents
AstrocytomaCVACE protocolCVB protocolCisplatin 1 MG/ML Injectable Solution

Narrower (21)

BriplatinCE-AVN protocolCISCA protocolCOMPE protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.
PURPOSE To compare the toxicities, tumor control, survival, and quality of life of nasopharyngeal cancer (NPC) patients treated… 
Highly Cited
2006
Highly Cited
2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four…
BACKGROUND To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan… 
Review
2006
Review
2006
The Discovery and Development of Cisplatin
Cisplatin is currently one of the most widely used anticancer drugs in the world. The unlikely events surrounding the discovery… 
Highly Cited
2005
Highly Cited
2005
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells
Previous work has shown that cisplatin (CDDP) becomes concentrated in lysosomes, and that acquired resistance to CDDP is… 
Review
2003
Review
2003
Cisplatin nephrotoxicity: molecular mechanisms.
Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of several human malignancies. The efficacy of… 
Review
2001
Review
2001
Is cisplatin-induced cell death always produced by apoptosis?
It is generally accepted that DNA damage and subsequent induction of apoptosis may be the primary cytotoxic mechanism of… 
Highly Cited
2000
Highly Cited
2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
BACKGROUND A randomized trial conducted by the Gynecologic Oncology Group (GOG, study #111) in the United States showed a better… 
Highly Cited
1995
Highly Cited
1995
Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin
THE success of cisplatin in cancer chemotherapy derives from its ability to crosslink DNA and alter the structure. Most cisplatin… 
Review
1991
Review
1991
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
In an effort to critically define the incidence and clinical characteristics of secondary responses to cisplatin-based therapy in… 
Highly Cited
1989
Highly Cited
1989
Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Treatment of human HL-60 or KG1A leukemia cells with the topoisomerase II inhibitor etoposide resulted in extensive DNA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)